The University of Chicago Header Logo

Connection

Gini Fleming to Pyridines

This is a "connection" page, showing publications Gini Fleming has written about Pyridines.
Connection Strength

0.717
  1. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010 Apr; 117(1):37-40.
    View in: PubMed
    Score: 0.313
  2. Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer. J Immunother Cancer. 2022 03; 10(3).
    View in: PubMed
    Score: 0.180
  3. Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clin Cancer Res. 2020 06 01; 26(11):2477-2486.
    View in: PubMed
    Score: 0.156
  4. Overcoming Taxane Resistance: Preclinical and Phase 1 Studies of Relacorilant, a Selective Glucocorticoid Receptor Modulator, with Nab-Paclitaxel in Solid Tumors. Clin Cancer Res. 2022 08 02; 28(15):3214-3224.
    View in: PubMed
    Score: 0.046
  5. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. Clin Cancer Res. 2011 Apr 01; 17(7):1956-63.
    View in: PubMed
    Score: 0.021
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.